Asceneuron SA

Asceneuron SA is a clinical-stage biotech company specializing in the development of orally bioavailable therapeutics for neurodegenerative disorders. Their primary focus is on targeting the abnormal protein aggregation that is a common feature of these diseases, specifically in the areas of Alzheimer's, Parkinson's, and orphan tauopathies. The company has two clinical-stage small molecule O-GlcNAcase (OGA) inhibitors in development. ASN90, licensed to Ferrer Pharmaceuticals, is being developed for the treatment of progressive supranuclear palsy (PSP). ASN51 is considered a potential best-in-class molecule for Alzheimer's disease. Asceneuron is also advancing pre-clinical development for Parkinson's, amyotrophic lateral sclerosis (ALS), and other neurodegenerative indications.

Asceneuron's commitment to developing treatments for a wide range of neurodegenerative diseases is reflected in its robust pipeline. They have secured significant funding from a syndicate of investors, including Novo Holdings, Sofinnova Partners, M Ventures, SR One, Orbimed, EQT, Johnson & Johnson Innovation – JJDC, Inc., and Kurma Partners. Asceneuron's focus on developing oral drugs provides a convenient and accessible treatment option for patients suffering from these debilitating disorders.

Asceneuron does not mention any details about job flexibility on their website or in their job postings.

Asceneuron provides employees with a dynamic and inspiring work environment that offers an overview of all stages of drug development. They foster a culture of individual accountability and pride in achievement, while prioritizing employee well-being and enjoyment in the work. The company's dedication to improving the lives of patients is reflected in their commitment to providing a fulfilling and rewarding work experience.

Asceneuron is a clinical-stage biotech company focused on developing oral therapies that target protein aggregation in the brain, a key factor in neurodegenerative diseases like Alzheimer’s and Parkinson’s. Their mission is to discover and develop truly effective treatments that halt disease progression and transform the lives of patients suffering from these debilitating disorders. They have a strong pipeline of clinical-stage O-GlcNAcase inhibitors that have shown promise in both preclinical and early clinical trials.

Asceneuron fosters a dynamic and inspiring work environment that emphasizes individual contributions and team pride. They are dedicated to improving the lives of patients and creating a fulfilling work experience for their employees, who are passionate about drug development and enjoy what they do.

Asceneuron's commitment to diversity, equity, and inclusion is evident in their diverse leadership team, which combines research and development excellence with business and fundraising experience. The company is dedicated to creating a dynamic and inspiring work environment that offers employees an overview of all stages of drug development. Asceneuron recognizes the value of a diverse workforce and is committed to providing equal opportunities for all employees, regardless of their background.